List of works - Peter B Gilbert

A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge

scientific article published on 01 September 2019

A framework for assessing immunological correlates of protection in vaccine trials

scientific article published on 2 October 2007

Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial

scientific article

Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial

scientific article

Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk

scientific article published on 01 November 2019

Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials

scientific article published on 22 May 2020

Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors

scientific article published on 24 June 2009

Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women

scientific article

Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family

scientific article

Antigenic competition in CD4+ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial

scientific article published on 01 November 2019

Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials

scientific article

Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160

scientific article published on 29 July 2004

COMPASS identifies T-cell subsets correlated with clinical outcomes

scientific article

Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials

scientific article published on 22 October 2020

Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial

scientific article

DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8+ T-Cell Responses by Interleukin-12 Plasmid DNA.

scientific article published on 20 September 2017

Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials

scientific article published on 2 September 2015

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

scientific article published on 30 December 2020

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

scientific article (publication date: 13 November 2008)

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

scientific article

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine

scientific article

Estimation of the optimal surrogate based on a randomized trial

scientific article published on 27 April 2018

Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E.

scientific article published on 26 July 2012

Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study)

scientific article

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial

scientific article

Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial

scientific article

HIV Vaccine Trials Network: activities and achievements of the first decade and beyond

scientific article

HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies

scientific article published on 30 July 2015

HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens

scientific article published on 07 February 2020

HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders

scientific article

HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1.

scientific article

HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition

scientific article published on July 2015

Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial

scientific article published on 12 February 2017

Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa

scientific article published on 01 September 2019

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

scientific article (publication date: 5 April 2012)

Immune-correlates analysis of an HIV-1 vaccine efficacy trial reveals an association of nonspecific interferon-γ secretion with increased HIV-1 infection risk: a cohort-based modeling study

scientific article

Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2

scientific article

Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees

scientific article published on 08 May 2013

Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk

scientific article published on 15 March 2021

Letter to the Editor on: The RV144 vaccine regimen was not associated with enhancement of infection

scientific article published on January 2015

MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load

scientific article

Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials

scientific article

Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America

scientific article published on 15 June 2020

Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation

scientific article published on 27 June 2006

Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants

scientific article

Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial

scientific article

Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features

article

Prospects for a safe COVID-19 vaccine

scientific article published on 19 October 2020

RV144 HIV-1 vaccination impacts post-infection antibody responses

scientific article published on 08 December 2020

Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study

scientific article

Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines

scientific article

Reply to Richie and Villasante

scientific article published on 29 November 2012

Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.

scientific article

Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines

scientific article published on 24 February 2020

Selection of HIV vaccine candidates for concurrent testing in an efficacy trial

scientific article published on 28 January 2016

Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants

scientific article

Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120.

scientific article published on 17 November 2017

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.

scientific article

The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.

scientific article

Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies

scientific article

Use of placebos in Phase 1 preventive HIV vaccine clinical trials

scientific article

V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.

scientific article

Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination

scientific article

Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses

scientific article

Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection

scientific article

Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG.

scientific article published on 9 May 2013

List of works by Peter B Gilbert

A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge

A framework for assessing immunological correlates of protection in vaccine trials

Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial

Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial

Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk

Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials

Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors

Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women

Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family

Antigenic competition in CD4+ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial

Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials

Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160

COMPASS identifies T-cell subsets correlated with clinical outcomes

Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials

Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial

DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8+ T-Cell Responses by Interleukin-12 Plasmid DNA.

Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine

Estimation of the optimal surrogate based on a randomized trial

Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E.

Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study)

FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial

Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial

HIV Vaccine Trials Network: activities and achievements of the first decade and beyond

HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies

HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens

HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders

HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1.

HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition

Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial

Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

Immune-correlates analysis of an HIV-1 vaccine efficacy trial reveals an association of nonspecific interferon-γ secretion with increased HIV-1 infection risk: a cohort-based modeling study

Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2

Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees

Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk

Letter to the Editor on: The RV144 vaccine regimen was not associated with enhancement of infection

MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load

Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials

Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America

Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation

Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants

Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial

Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features

Prospects for a safe COVID-19 vaccine

RV144 HIV-1 vaccination impacts post-infection antibody responses

Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study

Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines

Reply to Richie and Villasante

Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.

Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines

Selection of HIV vaccine candidates for concurrent testing in an efficacy trial

Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants

Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120.

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.

The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.

Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies

Use of placebos in Phase 1 preventive HIV vaccine clinical trials

V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.

Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination

Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses

Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection

Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG.